Videos

A dermatologist-turned-entrepreneur on why clinicians belong in dermatology's investment decisions, and what excites her about the field's direction.

Lisa Swanson, MD, on embracing failure in medicine and the oral JAK inhibitors advancing for hidradenitis suppurativa and alopecia areata.

Ashkan Shoamanesh, MD, discusses individualizing stroke prevention after ENRICH-AF, from LAAO to factor XI inhibitors to the ASPIRE trial.

Ashkan Shoamanesh, MD, explains ENRICH-AF's mixed stroke and bleeding results, and a dosing signal that may point to a safer approach.

Ashish Sarraju, MD, discusses phase 1 data showing a single dose of Kylo-11 durably reduced lipoprotein(a) through 48 weeks.

Luke Laffin, MD, discusses 1-year data showing CTX310 produced durable reductions in ANGPTL3, LDL cholesterol, and triglycerides.

Ronald Witteles, MD, explains why CARDIO-TTRansform's miss doesn't undermine TTR silencers as a class for treating ATTR-CM.

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.

Anjali Vaidya, MD, breaks down sotatercept's distinct effects on RV afterload, structure, and function in pulmonary arterial hypertension.

Steven Nissen, MD, shares key takeaways on AAV8, CTX310, and Kylo-11 gene and molecular therapies presented at ESC Congress 2026.

Erin Michos, MD, MHS, explains why hypertension risk rises earlier in women and how aldosterone and menopause drive that risk.

Gaetano De Ferrari, MD, breaks down VESALIUS-CV findings on evolocumab and first MI prevention across major infarct subtypes.

Philippe Gabriel Steg, MD, discusses the full results of the terminated trial, reflecting on their impact on the ongoing LIBREXIA-AF and LIBREXIA-Stroke trials.

Saakshi Khattri, MD, discusses a new JAAD dual Th17/type 2 signature study and what it means for personalized psoriasis care this awareness month.

Mahboobeh Mahdavinia, MD, says racial gaps in food allergy resolution reflect access to care, not biology.

Laura J. Maursetter, MD, discusses the case for standardized kidney screening protocols, transplant access, and medical education reform for the correctional population.

Ahmad Masri, MD, MS, discusses his presentation of the full results of the ACACIA-HCM trial at the ESC Congress 2026.

Saakshi Khattri, MD, discusses new oral psoriasis options and AAD 2026 weight-loss combination-therapy data in psoriatic disease.

Mahboobeh Mahdavinia, MD, PhD, discusses new FORWARD data showing peanut and shellfish allergies resolve far less often than milk, soy, or wheat.

Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

Cleveland Clinic's Ali Mehdi, MD, MEd, on the limits of current IgA nephropathy risk tools and where phenotyping could take treatment next.

Laura J. Maursetter, MD, discusses why early kidney disease screening and continuity of care are especially critical for justice-involved patients.

IMPACT-PLuS investigator Jennifer A. Dantzer says predictive biomarkers and formal remission testing remain unanswered questions in peanut OIT.

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and building patient trust and adherence.

A new meta-analysis found total pulse count predicted outcomes in a roughly linear pattern across sham-controlled trials of accelerated rTMS.

Downar says shorter sessions, accelerated schedules, and expanding neuroimaging maps have made TMS effective for more patients in far fewer visits.

Wojciech Zareba, MD, PhD, discusses his recent study comparing the efficacy of the KardiaMobile 6-Lead to Holter ambulatory ECGs.